Neurosteroids and Self-Reported Pain in Veterans Who Served in the U.S. Military after September 11, 2001

Pain Medicine

Volumn 11, Issue 10, 2010, Pages 1469-1476

  Kilts, Jason D ^a,b,c   Tupler, Larry A ^a,b,c   Keefe, Francis J ^a   Payne, Victoria M ^a,b,c   Hamer, Robert M ^d   Naylor, Jennifer C ^b,c   Calnaido, Rohana P ^c   Morey, Rajendra A ^a,b,c   Strauss, Jennifer L ^a,b,c   Parke, Gillian ^b,c   Massing, Mark W ^b   Youssef, Nagy A ^b,c   Shampine, Lawrence J ^a,b,c   Marx, Christine E ^a,b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA Mid Atlantic Mental Illness   (United States)

^d IL   (United States)

Author keywords

Allopregnanolone; DHEA; Neuroactive Steroid; Neurosteroid; Nociception; Pain; Pregnenolone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; PROGESTERONE;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANALGESIC ACTIVITY; ARTICLE; HEADACHE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MILITARY DEPLOYMENT; MUSCLE DISEASE; PAIN ASSESSMENT; POPULATION; RADIOIMMUNOASSAY; SELF REPORT; SMOKING; STEROID BLOOD LEVEL; SYMPTOM; TERRORISM; THORAX PAIN; TRANQUILIZING ACTIVITY; TRAUMATIC BRAIN INJURY; UNITED STATES; VETERAN;

EID: 77957245229     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00927.x     Document Type: Article

References (71)

1. Tanielian T, Jaycox LH, Schell TL. Invisible Wounds of War 2008, and, Invisible Wounds Study Team, Rand Report, Santa Monica, CA, Center for Military Health Policy Research
2. Gawande A. Casualties of war-Military care for the wounded from Iraq and Afghanistan. N Engl J Med 2004, 351(24):2471-5.
3. Hoge CW, Castro CA, Messer SC. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004, 351(1):13-22.
4. Hoge CW, McGurk D, Thomas JL. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008, 358(5):453-63.
5. Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C. Bringing the war back home: Mental health disorders among 103,788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Int Med 2007, 167(5):476-82.
6. Gironda RJ, Clark ME, Massengale JP, Walker RL. Pain among veterans of Operations Enduring Freedom and Iraqi Freedom. Pain Med 2006, 7(4):339-43.
7. Helmer DA, Chandler HK, Quigley KS. Chronic widespread pain, mental health, and physical role function in OEF/OIF veterans. Pain Med 2009, 10(7):1174-82.
8. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232(4753):1004-7.
9. Morrow AL, Suzdak PD, Paul SM. Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. Eur J Pharmacol 1987, 142(3):483-5.
10. Majewska MD, Schwartz RD. Pregnenolone-sulfate: An endogenous antagonist of the gamma-aminobutyric acid receptor complex in brain? Brain Res 1987, 404(1-2):355-60.
11. Majewska MD, Demirgoren S, London ED. Binding of pregnenolone sulfate to rat brain membranes suggests multiple sites of steroid action at the GABAA receptor. Eur J Pharmacol 1990, 189(4-5):307-15.
12. Majewska MD, Demirgoren S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990, 526(1):143-6.
13. Imamura M, Prasad C. Modulation of GABA-gated chloride ion influx in the brain by dehydroepiandrosterone and its metabolites. Biochem Biophys Res Commun 1998, 243(3):771-5.
14. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate γ-aminobutyric acidA receptor function through distinct sites. Brain Res 1999, 830(1):72-87.
15. Crawley JN, Glowa JR, Majewska MD, Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res 1986, 398(2):382-5.
16. Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5 α-pregnan-3 α-ol-20-one. Brain Res 1991, 565(2):263-8.
17. Bitran D, Klibansky DA, Martin GA. The neurosteroid pregnanolone prevents the anxiogenic-like effect of inescapable shock in the rat. Psychopharmacology 2000, 151(1):31-7.
18. Jain NS, Hirani K, Chopde CT. Reversal of caffeine-induced anxiety by neurosteroid 3-α-hydroxy-5-α-pregnane-20-one in rats. Neuropharmacology 2005, 48(5):627-38.
19. Landgren S, Aasly J, Backstrom T, Dubrovsky B, Danielsson E. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol Scand 1987, 131(1):33-42.
20. Belelli D, Bolger MB, Gee KW. Anticonvulsant profile of the progesterone metabolite 5 α-pregnan-3 α-ol-20-one. Eur J Pharmacol 1989, 166(2):325-9.
21. Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neurosteroids: Correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 1994, 270(3):1223-9.
22. Devaud LL, Purdy RH, Morrow AL. The neurosteroid, 3 α-hydroxy-5 α-pregnan-20-one, protects against bicuculline-induced seizures during ethanol withdrawal in rats. Alcohol Clin Exp Res 1995, 19(2):350-5.
23. Kokate TG, Cohen AL, Karp E, Rogawski MA. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996, 35(8):1049-56.
24. Kavaliers M. Inhibitory influences of the adrenal steroid, 3 α, 5 α-tetrahydrodeoxycorticosterone (correction of tetrahydroxycorticosterone) on aggression and defeat-induced analgesia in mice. Psychopharmacology 1988, 95(4):488-92.
25. Pinna G, Dong E, Matsumoto K, Costa E, Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci U S A 2003, 100(4):2035-40.
26. Kavaliers M, Wiebe JP. Analgesic effects of the progesterone metabolite, 3 α-hydroxy-5 α-pregnan-20-one, and possible modes of action in mice. Brain Res 1987, 415(2):393-8.
27. Winfree CJ, Coombs DW, DeLeo JA, Colburn RW. Analgesic effects of intrathecally-administered 3 α-hydroxy-5 α-pregnan-20-one in a rat mechanical visceral pain model. Life Sci 1992, 50(14):1007-12.
28. Frye CA, Duncan JE. Progesterone metabolites, effective at the GABAA receptor complex, attenuate pain sensitivity in rats. Brain Res 1994, 643(1-2):194-203.
29. Korneyev A, Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Horm Behav 1996, 30(1):37-43.
30. Kavaliers M, Perrot-Sinal TS, Desjardins DC, Cross-Mellor SK, Wiebe JP. Antinociceptive effects of the neuroactive steroid, 3α-hydroxy-5α-pregnan-20-one and progesterone in the land snail, Cepaea nemoralis. Neuroscience 2000, 95(3):807-12.
31. Pathirathna S, Brimelow BC, Jagodic MM. New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5α-reduced neuroactive steroids. Pain 2005, 114(3):429-43.
32. Yokoro CM, Pesquero SM, Turchetti-Maia RM, Francischi JN, Tatsuo MA. Acute phenobarbital administration induces hyperalgesia: Pharmacological evidence for the involvement of supraspinal GABA-A receptors. Braz J Med Biol Res 2001, 34(3):397-405.
33. Zou X, Lin Q, Willis WD. The effects of sympathectomy on capsaicin-evoked fos expression of spinal dorsal horn GABAergic neurons. Brain Res 2002, 958(2):322-9.
34. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol 2006, 54:1-27.
35. Mok WM, Krieger NR. Evidence that 5 α-pregnan-3 α-ol-20-one is the metabolite responsible for progesterone anesthesia. Brain Res 1990, 533(1):42-5.
36. Chen SC, Wu FS. Mechanism underlying inhibition of the capsaicin receptor-mediated current by pregnenolone sulfate in rat dorsal root ganglion neurons. Brain Res 2004, 1027(1-2):196-200.
37. Chen SC, Liu BC, Chen CW, Wu FS. Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats. Biochem Biophys Res Commun 2006, 349(2):626-33.
38. Khoromi S, Muniyappa R, Nackers L. Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab 2006, 91(11):4313-8.
39. Finset A, Overlie I, Holte A. Musculo-skeletal pain, psychological distress, and hormones during the menopausal transition. Psychoneuroendocrinology 2004, 29(1):49-64.
40. Finckh A, Berner IC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005, 32(7):1336-40.
41. Genazzani AR, Inglese S, Lombardi I. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. Aging Male 2004, 7(2):133-43.
42. Mechlin B, Morrow AL, Maixner W, Girdler SS. The relationship of allopregnanolone immunoreactivity and HPA-axis measures to experimental pain sensitivity: Evidence for ethnic differences. Pain 2007, 131(1-2):142-52.
43. Derogatis LR. Symptom Checklist-90-R, Administration, Scoring, and Procedures Manual 1994, 3rd, edition, Minneapolis, MN, National Computer Systems
44. Gilron I, Coderre TJ. Preemptive analgesic effects of steroid anesthesia with αxalone in the rat formalin test. Evidence for differential GABA(A) receptor modulation in persistent nociception. Anesthesiology 1996, 84(3):572-9.
45. Goodchild CS, Robinson A, Nadeson R. Antinociceptive properties of neurosteroids IV: Pilot study demonstrating the analgesic effects of αdolone administered orally to humans. Br J Anaesth 2001, 86(4):528-34.
46. Nadeson R, Goodchild CS. Antinociceptive properties of neurosteroids III: Experiments with αdolone given intravenously, intraperitoneally, and intragastrically. Br J Anaesth 2001, 86(5):704-8.
47. Winter L, Nadeson R, Tucker AP, Goodchild CS. Antinociceptive properties of neurosteroids: A comparison of αdolone and αxalone in potentiation of opioid antinociception. Anesth Analg 2003, 97(3):798-805.
48. Peebles JE, McWilliams LA, MacLennan R. A comparison of symptom checklist 90-revised profiles from patients with chronic pain from whiplash and patients with other musculoskeletal injuries. Spine 2001, 26(7):766-70.
49. Marx CE, Trost WT, Shampine L. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology 2006, 186(3):462-72.
50. Marx CE, Trost WT, Shampine LJ. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 2006, 60(12):1287-94.
51. Kay T, Harrington DE, Adams R. Definition of mild traumatic brain injury. J Head Trauma Rehabil 1993, 8(3):86-7.
52. Ivins BJ, Schwab KA, Warden D. Traumatic brain injury in U.S. Army paratroopers: Prevalence and character. J Trauma 2003, 55(4):617-21.
53. Reinert DF, Allen JP. The alcohol use disorders identification test: An update of research findings. Alcohol Clin Exp Res 2007, 31(2):185-99.
54. Genazzani AR, Petraglia F, Bernardi F. Circulating levels of allopregnanolone in humans: Gender, age, and endocrine influences. J Clin Endocrinol Metab 1998, 83(6):2099-103.
55. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001, 49(9):788-97.
56. Genazzani AD, Luisi M, Malavasi B. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 2002, 146(3):347-56.
57. Smith CD, Wekstein DR, Markesbery WR, Frye CA. 3α,5α-THP: A potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology 2006, 186(3):481-5.
58. Ghezzi P, Santo ED, Sacco S. Neurosteroid levels are increased in vivo after LPS treatment and negatively regulate LPS-induced TNF production. Eur Cytokine Netw 2000, 11(3):464-9.
59. He J, Evans CO, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 2004, 189(2):404-12.
60. Mellon S, Gong W, Griffin LD. Niemann pick type C disease as a model for defects in neurosteroidogenesis. Endo Res 2004, 30(4):727-35.
61. Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004, 10(7):704-11.
62. Ahmad I, Lope-Piedrafita S, Bi X. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res 2005, 82(6):811-21.
63. Ghoumari AM, Ibanez C, El-Etr M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003, 86(4):848-59.
64. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004, 123(2):349-59.
65. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005, 22(1):106-18.
66. Uomoto JM, Esselman PC. Traumatic brain injury and chronic pain: Differential types and rates by head injury severity. Arch Phys Med Rehabil 1993, 74(1):61-4.
67. Lahz S, Bryant RA. Incidence of chronic pain following traumatic brain injury. Arch Phys Med Rehabil 1996, 77(9):889-91.
68. Bryant RA, Marosszeky JE, Crooks J, Baguley IJ, Gurka JA. Interaction of posttraumatic stress disorder and chronic pain following traumatic brain injury. J Head Trauma Rehabil 1999, 14(6):588-94.
69. Walker WC, Seel RT, Curtiss G, Warden DL. Headache after moderate and severe traumatic brain injury: A longitudinal analysis. Arch Phys Med Rehabil 2005, 86(9):1793-800.
70. Batten SV, Pollack SJ. Integrative outpatient treatment for returning service members. J Clin Psychol 2008, 64(8):928-39.
71. VHA Office of Public Health and Environmental Hazards. Reports on Returning Combat Veterans. 2008, Washington, DC, Veterans Health Administration